$4.59
1.08% day before yesterday
Nasdaq, Nov 28, 07:00 pm CET
ISIN
US03528H1095
Symbol
ANIX

Anixa Biosciences, Inc. Stock price

$4.59
+0.35 8.25% 1M
+2.05 80.71% 6M
+2.27 97.84% YTD
+1.28 38.67% 1Y
-0.35 7.09% 3Y
+1.95 73.86% 5Y
+1.78 63.35% 10Y
-14.16 75.52% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.05 1.08%
ISIN
US03528H1095
Symbol
ANIX
Industry

Key metrics

Basic
Market capitalization
$151.1m
Enterprise Value
$135.1m
Net debt
positive
Cash
$16.0m
Shares outstanding
32.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.1
Financial Health
Equity Ratio
92.6%
Return on Equity
-62.8%
ROCE
-76.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-12.0m | $-13.2m
Net Income
$-11.1m | $-11.7m
Free Cash Flow
$-6.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
12.6% | 4.3%
Net Income
10.0% | 6.6%
Free Cash Flow
18.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
$-0.2
Short interest
2.0%
Employees
5
Rev per Employee
$0.0
Show more

Is Anixa Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Anixa Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Anixa Biosciences, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Anixa Biosciences, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Anixa Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.58 6.58
8% 8%
-
- Research and Development Expense 5.41 5.41
17% 17%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
13% 13%
-
Net Profit -11 -11
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anixa Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anixa Biosciences, Inc. Stock News

Neutral
Seeking Alpha
12 days ago
Anixa Biosciences, Inc. ( ANIX ) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs November 11, 2025 2:00 PM EST Company Participants Amit Kumar - CEO, Chairman & Co-Chair of CBAB Conference Call Participants Robert Sassoon - Water Tower Research LLC Presentation Robert Sassoon Water Tower Research LLC Hello, everybody. I'm Robert Sassoon.
Neutral
PRNewsWire
12 days ago
SAN JOSE, Calif. , Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) approved "liraltagene autoleucel" for the non-proprietary name of the Company's nove...
Neutral
GlobeNewsWire
17 days ago
Water Tower Research (WTR) issued the following statement regarding a technical issue that occurred during its recent Fireside Chat with Anixa Biosciences, Inc. (NASDAQ: ANIX), held on Tuesday, November 11, 2025. Water Tower Research (WTR) issued the following statement regarding a technical issue that occurred during its recent Fireside Chat with Anixa Biosciences, Inc. (NASDAQ: ANIX), held on...
More Anixa Biosciences, Inc. News

Company Profile

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Head office United States
CEO Amit Kumar
Employees 5
Founded 1982
Website www.anixa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today